Tesamorelin (Egrifta) side effects: the documented, label-monitored profile

Tesamorelin is unusual among the peptides people research online: it is an FDA-approved drug. Marketed as Egrifta (and now Egrifta SV/WR) for HIV-associated lipodystrophy, it cleared two pivotal phase 3 trials, which means — unlike most peptides sold as research chemicals — it has a genuine, label-documented adverse-effect profile drawn from controlled human studies.^[1] So instead of the usual “the data don’t exist yet” caveat, we can actually tell you what was observed, how the label frames it, and what the mechanism-based concerns are. The goal here is honesty, not alarm: the most common events are local and musculoskeletal, and the deeper questions cluster around the growth-hormone axis the drug is designed to stimulate.

The most commonly reported side effects

Across the pivotal program and its pooled safety analysis, the adverse events seen more often with tesamorelin than placebo were dominated by injection-site reactions (the drug is a daily subcutaneous injection) and a cluster of musculoskeletal complaints — arthralgia (joint pain), myalgia (muscle pain), pain in the extremities, and joint stiffness.^[2] Peripheral edema (fluid-related swelling, typically in the legs) is also a recognized, mechanism-consistent effect, as fluid retention is a classic consequence of stimulating growth-hormone secretion. The pooled phase 3 analysis with safety-extension data described tesamorelin as generally well tolerated over the studied period, with the events above being the ones that distinguished it from placebo rather than a long tail of severe reactions.^[3] The Egrifta SV prescribing information lists these same categories — arthralgia, injection-site erythema/pruritus, pain in extremity, peripheral edema, myalgia — among its most frequent adverse reactions.^[4]

We have deliberately not invented a precise percentage table here. The exact frequencies depend on the specific population, formulation, and trial, and reproducing label numbers out of context tends to mislead more than it informs. The reliable takeaway is the pattern: local injection effects plus joint/muscle and fluid-related symptoms are what to expect most often.

The growth-hormone axis: the concern that defines the label

Tesamorelin is a growth-hormone-releasing factor (GRF) analogue — it works by prompting the pituitary to release the body’s own growth hormone, which in turn raises IGF-1. That mechanism is the whole point of the drug, but it is also the source of its most important safety considerations, and it is why the FDA label instructs clinicians to monitor IGF-1 during treatment.^[4] A meaningfully or persistently elevated IGF-1 is the signal that the GH axis is being pushed harder than intended, and the label directs dose interruption or discontinuation in that setting.

The second mechanism-based concern is glucose tolerance. Growth hormone is counter-regulatory to insulin, so any GH-raising therapy invites the question of whether it worsens blood sugar. This was tested directly: a randomized, placebo-controlled trial of tesamorelin in patients with type 2 diabetes examined exactly this safety question, and the prescribing information reflects the resulting guidance to monitor glucose status, with particular care in people who already have diabetes or impaired glucose tolerance.^[5] The broader trial record, including a JAMA study of tesamorelin’s effects on visceral and liver fat, similarly tracked metabolic and IGF-1 endpoints rather than treating them as afterthoughts.^[6] None of this makes tesamorelin uniquely dangerous — it makes it a drug whose benefits and its monitored risks share the same mechanism.

Contraindications and who should not take it

Because the drug elevates the GH/IGF-1 axis, the label carries mechanism-driven contraindications. It is contraindicated in the presence of active malignancy, given the theoretical concern that raising IGF-1 could promote tumor growth, and any pre-existing malignancy should be inactive and its treatment complete before starting. It is also contraindicated in pregnancy (there is no benefit to the approved indication during pregnancy and fetal risk cannot be excluded), and in patients with disruption of the hypothalamic-pituitary axis from certain causes, or with known hypersensitivity to tesamorelin or mannitol.^[4] A review of the agent for HIV-associated lipodystrophy frames these the same way — a tolerable profile in the approved population, governed by GH-axis-related cautions.^[7] These are not edge cases to gloss over; they are the boundaries the approval was built around.

The modern off-label and compounded-supply caveat

Here is the practical wrinkle for anyone encountering tesamorelin outside its approved use. The documented safety profile above comes from the FDA-approved, manufactured product studied at defined doses in a defined population. Much of the current interest in tesamorelin — for body composition, “longevity,” or general GH-axis optimization — involves compounded or research-grade material used off-label, often at doses and in people the trials never evaluated. In that setting you inherit two layers of uncertainty at once: the inherent GH-axis risks (IGF-1 elevation, glucose effects, edema) plus the unknowns of a supply chain that may not match the purity, potency, or identity of the approved drug. The label’s monitoring instructions — check IGF-1, watch glucose — are precisely what the unsupervised off-label user is least likely to have in place. The honest framing is that tesamorelin’s reassuring trial record belongs to the approved product used as studied, and does not automatically transfer to an unmonitored, compounded regimen.

The bottom line

Tesamorelin is one of the few peptides where a real answer to “what are the side effects?” exists. Most often: injection-site reactions, joint and muscle pain, and peripheral edema. The defining concerns are mechanism-based — rising IGF-1 (which the label monitors), effects on glucose tolerance, and contraindications in active malignancy and pregnancy. Used as approved and monitored, it has a characterized, manageable profile; used off-label from unverified supply without IGF-1 and glucose monitoring, those same mechanisms become harder to manage safely. For the efficacy picture and dosing context, see our reads on the tesamorelin (Egrifta) evidence base and on tesamorelin dosage.